Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin  Ornella Soro, Adelaide.

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Molecular evolution of Mycobacterium tuberculosis
Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm  S.O. Simons, T. van der Laan,
Rapid streptococcal testing for sore throat and antibiotic resistance
L. Boyanova  Clinical Microbiology and Infection 
New epidemiology of Staphylococcus aureus infection in Asia
Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern.
Gut bacterial microbiota and obesity
Salvage therapy for multidrug-resistant tuberculosis
Approach to diagnosis of infective endocarditis
Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients 
Interaction of insulin and Burkholderia cepacia
Herpes zoster in non-hospitalized children
Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis  C.-C. Shu, J.-T. Wang, J.-Y. Wang, C.-J. Yu,
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
J.-P. Van geertruyden  Clinical Microbiology and Infection 
Use of antimicrobials and resistance in bacteria isolated from blood cultures in a Danish county from 1992 to 1995  Thomas Lund S⊘rensen, Niels Frimodt-M⊘ller,
E. Lindberg, I. Adlerberth, A.E. Wold 
E. Cambau, M. Drancourt  Clinical Microbiology and Infection 
Rapid streptococcal testing for sore throat and antibiotic resistance
Louis Pasteur, from crystals of life to vaccination
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species  Jacques Dubois, Claude St-Pierre  Clinical.
Results from a mathematical model for human monocytic ehrlichiosis
Vector control: a cornerstone in the malaria elimination campaign
C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins
Sofie Arens, Jan Verhaegen, Ludo Verbist 
Training for the infectious diseases speciality in Norway
E.C. Böttger  Clinical Microbiology and Infection 
Interaction of insulin and Burkholderia cepacia
Cephalosporins: a pharmacological update
Epidemiology of opportunistic infections in AIDS patients
CMI editorial report 2011 Clinical Microbiology and Infection
S. Borrell, S. Gagneux  Clinical Microbiology and Infection 
Salvage therapy for multidrug-resistant tuberculosis
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
Levofloxacin in the treatment of ventilator-associated pneumonia
Metagenomics and probiotics
W.A. Craig  Clinical Microbiology and Infection 
Systematic review of antibiotic consumption in acute care hospitals
Community-acquired pneumonia: epidemiologic and clinical consideration
Abstracts cont. Clinical Microbiology and Infection
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci  H.L. DuPont, Z.-D. Jiang  Clinical Microbiology.
A.P. Underwood, J. Green  Clinical Microbiology and Infection 
Andrew M. Middleton, Maureen V. Chadwick, Harold Gaya 
Increased in vitro fitness of multi- and extensively drug-resistant F15/LAM4/KZN strains of Mycobacterium tuberculosis  C.C. Naidoo, M. Pillay  Clinical.
Clinical infection services—the Leiden experience
Effect of antibiotics, alone and in combination, on Panton–Valentine leukocidin production by a Staphylococcus aureus reference strain  O. Dumitrescu,
An after-hours clinical liaison blood culture service—is it worth it?
Clinical Microbiology and Infection
The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae  I. Gustafsson, O. Cars  Clinical Microbiology.
Examination of specimens for mycobacteria in clinical laboratories in 21 countries: a 10- year review of the UK National Quality Assessment Scheme for.
Can pharmacokinetic–pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?  P. Courvalin  Clinical Microbiology and.
Overview of cefixime use in community-acquired infections
K. Kaier, N.T. Mutters, U. Frank  Clinical Microbiology and Infection 
The atypical pneumonias: clinical diagnosis and importance
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
Virology: a scientific discipline facing new challenges
Modelling during an emergency: the 2009 H1N1 influenza pandemic
New oral cephalosporins in pediatric community-acquired infections
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
Abstracts Clinical Microbiology and Infection
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Vincent Calvez, Marc Grandadam  Clinical Microbiology and Infection 
Presentation transcript:

Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin  Ornella Soro, Adelaide Pesce, Monica Raggi, Eugenio A. Debbia, Gian Carlo Schito  Clinical Microbiology and Infection  Volume 3, Issue 1, Pages 147-151 (February 1997) DOI: 10.1111/j.1469-0691.1997.tb00272.x Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Growth rates of strains 1 to 5 of M. tuberculosis, expressed as growth indices as a function of time, when tested with four rifaximin concentrations (A, 6 ng/mL; B, 20 ng/mL; C, 90 ng/mL; D, 270 ng/mL), compared with growth indexes of controls (C1 to C5) in the absence of antibiotic. Treated cultures, solid lines; control, dotted lines. Clinical Microbiology and Infection 1997 3, 147-151DOI: (10.1111/j.1469-0691.1997.tb00272.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Growth rates of strains 1 to 5 of M. tuberculosis, expressed as growth indices as a function of time, when tested with four rifaximin concentrations (A, 6 ng/mL; B, 20 ng/mL; C, 90 ng/mL; D, 270 ng/mL), compared with growth indexes of controls (C1 to C5) in the absence of antibiotic. Treated cultures, solid lines; control, dotted lines. Clinical Microbiology and Infection 1997 3, 147-151DOI: (10.1111/j.1469-0691.1997.tb00272.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions